Trinity Biotech (NASDAQ:TRIB) announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.06), MarketWatch Earnings reports. The company had revenue of $22.03 million during the quarter. Trinity Biotech had a negative net margin of 23.81% and a positive return on equity of 3.20%.
Shares of NASDAQ:TRIB opened at $2.18 on Friday. Trinity Biotech has a 52 week low of $2.13 and a 52 week high of $5.25. The company has a market capitalization of $52.65 million, a price-to-earnings ratio of 18.25 and a beta of 1.52. The company has a current ratio of 4.30, a quick ratio of 2.74 and a debt-to-equity ratio of 1.86.
Several large investors have recently made changes to their positions in the business. Lapides Asset Management LLC increased its stake in shares of Trinity Biotech by 2.1% during the first quarter. Lapides Asset Management LLC now owns 655,600 shares of the company’s stock valued at $1,868,000 after acquiring an additional 13,700 shares during the period. Renaissance Technologies LLC increased its stake in shares of Trinity Biotech by 3.0% during the first quarter. Renaissance Technologies LLC now owns 613,811 shares of the company’s stock valued at $1,749,000 after acquiring an additional 18,100 shares during the period. BlackRock Inc. acquired a new position in shares of Trinity Biotech during the fourth quarter valued at approximately $141,000. Finally, Hunter Associates Investment Management LLC increased its stake in shares of Trinity Biotech by 10.8% during the first quarter. Hunter Associates Investment Management LLC now owns 1,078,610 shares of the company’s stock valued at $3,074,000 after acquiring an additional 104,928 shares during the period. Institutional investors own 54.51% of the company’s stock.
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes.
Read More: Quiet Period Expirations
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.